Your institution may have access to this item. Find your institution then sign in to continue.
Title
Efficacy and tolerability of lumiracoxib 200 mg once daily for treatment of primary dysmenorrhea: results from two randomized controlled trials.
Authors
Daniels, Stephen; Gitton, Xavier; Zhou, Wenchun; Stricker, Kirstin; Barton, Scott
Abstract
Nonsteroidal anti-inflammatory drugs (NSAIDs) are established as treatment for managing pain associated with primary dysmenorrhea. However, the efficacy and tolerability of lumiracoxib 200 mg once daily (q.d.) has not previously been examined in primary dysmenorrhea.
Publication
Journal of women's health (2002), 2008, Vol 17, Issue 3, p423